BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Moderate Buy” from Analysts

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has earned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $389.1538.

Several research firms have recently weighed in on ONC. Guggenheim raised their price objective on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wolfe Research began coverage on BeOne Medicines in a research note on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective for the company. Royal Bank Of Canada raised their price objective on BeOne Medicines from $423.00 to $425.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Wells Fargo & Company began coverage on BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective for the company. Finally, Jefferies Financial Group lowered BeOne Medicines from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $420.00 to $290.00 in a research note on Monday, March 16th.

BeOne Medicines Stock Down 3.1%

Shares of ONC stock opened at $290.58 on Friday. The stock has a market cap of $31.88 billion, a PE ratio of 65.01 and a beta of 0.50. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The business’s fifty day moving average is $301.92 and its 200-day moving average is $320.91. BeOne Medicines has a 1 year low of $239.25 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities analysts expect that BeOne Medicines will post 5.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Alessandro Riva sold 212 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $309.51, for a total value of $65,616.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Margaret Dugan sold 212 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $309.60, for a total value of $65,635.20. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 1,641 shares of company stock valued at $505,791. 6.19% of the stock is owned by insiders.

Institutional Trading of BeOne Medicines

A number of hedge funds have recently modified their holdings of the business. Bank of America Corp DE lifted its holdings in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of BeOne Medicines in the first quarter valued at $3,475,000. EverSource Wealth Advisors LLC lifted its holdings in shares of BeOne Medicines by 16.4% in the first quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock valued at $110,000 after purchasing an additional 52 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of BeOne Medicines by 3.5% in the first quarter. Royal Bank of Canada now owns 70,391 shares of the company’s stock valued at $20,905,000 after purchasing an additional 2,399 shares in the last quarter. Finally, Rokos Capital Management LLP purchased a new stake in shares of BeOne Medicines in the first quarter valued at $4,256,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.